肝硬化患者合并细菌感染的临床特征分析
摘要
关键词
全文:
PDF参考
[1]李浩,程璠,郭东星,等. 肝硬化患者并发自发性细菌性腹膜炎的高危特征与潜在风险分析[J]. 中国卫生统计,2020,37
(5):664-666+671.
[2]陈艳,林瑞,陈竹,等. 2012 至 2018 年某院肝硬化并自发性细菌性腹膜炎的病原学及耐药性分析[J]. 肝脏,2020,25(2):
166-169.
[3]苏娟,王晓勇,张惠林. 肝硬化患者合并自发性细菌性腹膜炎的危险因素分析[J]. 贵州医药,2021,45(9):1375-1376.
[4]李翠如,武丽,平采艳,等. 微生态制剂治疗乙型肝炎肝硬化并发自发性细菌性腹膜炎患者临床疗效分析[J]. 实用肝脏病
杂志,2020,23(6):845-848.
[5]应妩,王毓三,申子瑜。全国 J 临床检验操作规程 fMl.3 版.南京:东南大学出版社,2006:128.129.143—144.
[6]Ferrarese A,Frigo A C,Russo F P,et al. Diagnostic and prognostic role of presepsin in patients with cirrhosis and bact
erial infection[J]. Digestive and Liver Disease,2020,52(1):e15-e16.
[7]陈勇,陈宇,侯星雁,等. 失代偿期肝硬化患者并自发性细菌性腹膜炎抗感染治疗中 PCT 表达的意义[J]. 肝脏,2020,25
(6):617-619.
[8]Patel K,Patel A,Desai J,et al. Patient Characteristics and In-Hospital Outcomes of Clostridium difficile Infection in Pat
ients With Liver Cirrhosis[J]. The American Journal of Gastroenterology,2020,115(1):S549.
[9]李苏萌,刘京,郑昕. 肝硬化合并自发性细菌性腹膜炎致病菌特征及抗菌治疗方案[J]. 中华肝脏病杂志,2021,29(7):7
16-720.
[10]Sasso R,Yassine A A,Deeb L . Predictors of Development of Hepatorenal Syndrome in Hospitalized Cirrhotic Patients w
ith Acute Kidney Injury[J]. Journal of Clinical Medicine,2021,10(23):5621.
[11]林升龙,林明华,王香梅,等. 乙型肝炎病毒相关慢性肝病患者的能量代谢特点与继发细菌感染的风险[J]. 中华肝脏病杂
志,2021,29(6):558-564.
[12]周艳兰,宋志韬,龚晶,等. 肝硬化合并自发性细菌性腹膜炎病原菌及 PGE2,D-二聚体,NGAL 的诊断效能[J]. 中华医
院感染学杂志,2020,30(20):3076-3079.
[13]Shi Q,Xiong K,Ding B,et al. Clinical characteristics of cirrhosis patients with umbilical vein recanalization:A retrospe
ctive analysis.[J]. Medicine,2021,100(35):e26774.
[14]程爱琼,施伎蝉,宁洪叶,等. 肝硬化患者合并肺部感染痰培养中微生物谱及抗生素耐药分析[J]. 中国卫生检验杂志,2
020,30(21):2598-2601.
[15]Trebicka J,Fernandez J,Papp M,et al. PREDICT identifies precipitating events associated with the clinical course of a
cutely decompensated cirrhosis - ScienceDirect[J]. Journal of Hepatology,2021,74(5):1097-1108.
(33 摘要 Views, 37 PDF Downloads)
Refbacks
- 当前没有refback。